Boehringer Ingelheim and Harvard scientists establish a research alliance to find novel ...

• Fibrotic diseases represent a serious healthcare problem, which potentially results in disability and even death for millions of people worldwide with currently only limited effective treatment options available
• New research alliance aims to find better treatments for diseases like idiopathic pulmonary fibrosis (IPF), chronic kidney disease (CKD) and nonalcoholic steatohepatitis (NASH) by investigating common mechanisms
• Alliance is open for other Harvard-affiliated groups interested in contributing to fibrosis research and will grow over time

(BUSINESS WIRE)-- Boehringer Ingelheim today announced it has established a research collaboration with the Harvard Stem Cell Institute's - Harvard Fibrosis Network to discover new ways of treating fibrotic diseases such as idiopathic pulmonary fibrosis (IPF), chronic kidney disease (CKD) and nonalcoholic steatohepatitis (NASH). ...

Source : http://me-newswire.net//news/18129/en...